Abemaciclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor was investigated in the JUNIPER clinical trials against erlotinib in patients with KRAS mutant (exon 12 or exon 13) advanced NSCLC. Here, KRAS is linked to non-small cell lung carcinoma.